Basic Information
| LncRNA/CircRNA Name | FTX |
| Synonyms | FTX, LINC00182, MIR374AHG, NCRNA00182 |
| Region | GRCh38_X:73946555-74293574 |
| Ensemble | ENSG00000230590 |
| Refseq | NR_028379 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | acute myeloid leukemia |
| ICD-0-3 | NA |
| Methods | Microarray, qPCR, Western blot, Flow cytometry assay, RIP, etc. |
| Sample | AML cell lines(U937, THP-1). |
| Expression Pattern | up-regulated |
| Function Description | The observation suggested that high-mannose N-glycans and mannosyltransferase ALG3 affected drug-resistance in AML cells. FTX/miR-342/ALG3 axis could potentially be used for the targets to overcome therapeutic resistance in AML. Functionally, we found that FTX directly interacted with miR-342 to regulate ALG3 expression and function, including ADR-resistant cell growth and apoptosis. Kaplan-Meier overall survival curves (OS) was observed based on ALG3 level. Data were the means?SD of triplicate determinants (*p < 0.05). |
| Pubmed ID | 29880818 |
| Year | 2018 |
| Title | Aberrant mannosylation profile and FTX/miR-342/ALG3-axis contribute to development of drug resistance in acute myeloid leukemia. |
External Links
| Links for FTX | GenBank HGNC NONCODE |
| Links for acute myeloid leukemia | OMIM COSMIC |